Neogen (NEOG) Q3 2025 Earnings Call Transcript

Q3 revenue was $221M and management cut full-year revenue guidance to ~ $895M and adjusted EBITDA to ~$195M; adjusted EPS was $0.10 (vs $0.12 YoY). Gross margin fell to 49.9% (-120 bps YoY) and free cash flow guidance moved to a ~$20M outflow, while Q3 FCF was an outflow of ~$14M. CEO John Adent announced he will step down and the company continues 3M/Petrifilm integration with initial test production targeted for fall 2025; Food Safety ex-sample-collection core grew 7% but consolidated core growth was only +0.2% with >400 bps headwind from genomics/sample collection. Management flagged tariff exposure of roughly $29–30M on a 12-month run rate (two-thirds tied to China) and cited ~ $6M of revenue shortfall in the quarter from macro/distributor hesitancy.

Analysis

Recent developments have amplified two distinct drivers of short‑term volatility: policy/tariff uncertainty that materially raises the cost and demand risk for internationally sourced consumables, and an operationally lumpy integration that will create a multi‑quarter pattern of uneven unit economics. Expect distributor behavior to be the proximate amplifying mechanism — cautious stocking decisions can produce a shallow trough that looks like secular weakness but is reversible once clarity on tariffs and sourcing emerges.

A SKU‑by‑SKU manufacturing transition creates predictable second‑order margin pain: overlapping production, validation yields, and dual logistics will depress reported margins and cash conversion while the new footprint proves out. That sequencing means headline operating metrics will remain noisy even if underlying demand stabilizes, so investors should discount next few quarters and focus on unit economics post‑validation.

Leadership turnover increases execution risk on commercial re‑acceleration and on timing of any portfolio monetizations; proceeds that are guided to deleveraging become a timing/certainty variable that the market will heavily discount until cash actually hits the balance sheet. Conversely, once domestic production proves cost parity, the company gains pricing and channel leverage versus import‑dependent rivals — a structural upside that’s currently underappreciated by the market.

Net: asymmetric reward profile — meaningful downside if tariffs/distributor pause extend, but telescoped upside if SKU validation and one or two portfolio transactions close in the next 9–18 months. Trading and hedging should therefore separate the short‑window policy/earnings risks from the longer‑dated operational optionality.

Key Decisions for Investors

• Directional hedge (near term): Buy a 3–6 month NEOG put spread (buy near‑ATM put, sell 20–30% OTM put) to capture guide/ tariff risk while limiting premium. Target a 2–3x payoff if headline revisions continue; unwind on a confirmed policy clarification or a distributor restocking print.
• Event‑driven long (contrarian, 12–24 months): Purchase a 12–24 month NEOG call spread (bull‑call spread with strikes chosen to limit premium) to play re‑rating contingent on manufacturing SKU validation and one completed portfolio sale. Risk = premium; reward skewed 3x+ if margin trajectory and FCF inflect.
• Relative value pair (6–12 months): Short NEOG equity and go long a diversified industrial/food‑safety name (e.g., MMM) to isolate execution/tariff pain vs. broader industrial resilience. Size as a market‑neutral pair; close if NEOG outperforms peer by >15% or after confirmed asset sale.
• Liquidity/cash‑flow watchlist: If management announces definitive monetization with committed proceeds, rotate a portion of short exposure into sizeable long equity positions within two trading days post‑close — target asymmetric IRR if proceeds are used to materially reduce leverage and integration CapEx falls.